Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma
Background: Our goal was to evaluate the clinical impact of local and systemic imaging in secondary breast angiosarcoma (SBAS) at diagnosis (DX) and in follow-up (FU). Materials and Methods: Singe-center retrospective review of SBAS treated from 1/2007-7/2020. Clinicopathologic data was collected, i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Surgery in Practice and Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666262022000250 |
| _version_ | 1798032296811429888 |
|---|---|
| author | Kelsey E. Larson Benjamin Powers Jason Gatewood Amanda L. Amin Lyndsey J. Kilgore Jamie L. Wagner Christa R. Balanoff |
| author_facet | Kelsey E. Larson Benjamin Powers Jason Gatewood Amanda L. Amin Lyndsey J. Kilgore Jamie L. Wagner Christa R. Balanoff |
| author_sort | Kelsey E. Larson |
| collection | DOAJ |
| description | Background: Our goal was to evaluate the clinical impact of local and systemic imaging in secondary breast angiosarcoma (SBAS) at diagnosis (DX) and in follow-up (FU). Materials and Methods: Singe-center retrospective review of SBAS treated from 1/2007-7/2020. Clinicopathologic data was collected, including local and systemic imaging at DX and FU. The clinical impact of imaging was evaluated. Results: Twenty patients had SBAS diagnosed 10.6±6.7 years following their index BC. All were diagnosed on exam. Mammogram, ultrasound, and breast MRI were commonly performed concurrently with DX (2.4 studies per patient) but did not impact clinical management. In-breast imaging extent of disease did not correlate with pathologic extent of disease (p=0.49). Systemic staging uncommonly identified asymptomatic metastatic disease (5%). During FU, 90% of recurrences were identified by exam or new symptoms, not routine imaging. Conclusions: SBAS extent is not reliably estimated on targeted breast imaging. Asymptomatic metastatic disease is uncommon but targeted evaluation of new symptoms is warranted given high likelihood of identifying metastasis. Additional data is needed to define optimum imaging timing and modalities for SBAS. |
| first_indexed | 2024-04-11T20:11:52Z |
| format | Article |
| id | doaj.art-760cb5418fa34dc0864b9bf562374366 |
| institution | Directory Open Access Journal |
| issn | 2666-2620 |
| language | English |
| last_indexed | 2024-04-11T20:11:52Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Surgery in Practice and Science |
| spelling | doaj.art-760cb5418fa34dc0864b9bf5623743662022-12-22T04:05:06ZengElsevierSurgery in Practice and Science2666-26202022-09-0110100081Clinical Impact of Systemic Staging Studies in Secondary Breast AngiosarcomaKelsey E. Larson0Benjamin Powers1Jason Gatewood2Amanda L. Amin3Lyndsey J. Kilgore4Jamie L. Wagner5Christa R. Balanoff6Department of Surgery, Division of Breast Surgery, University of Kansas Medical Center, Kansas City KS 66160; Corresponding author at: 3901 Rainbow Blvd, Mail Stop 2005, Kansas City, KS, 66160Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City KS 66160Department of Radiology, Division of Breast Imaging, University of Kansas Medical Center, Kansas City KS 66160Department of Surgery, Division of Breast Surgery, University of Kansas Medical Center, Kansas City KS 66160Department of Surgery, Division of Breast Surgery, University of Kansas Medical Center, Kansas City KS 66160Department of Surgery, Division of Breast Surgery, University of Kansas Medical Center, Kansas City KS 66160Department of Surgery, Division of Breast Surgery, University of Kansas Medical Center, Kansas City KS 66160Background: Our goal was to evaluate the clinical impact of local and systemic imaging in secondary breast angiosarcoma (SBAS) at diagnosis (DX) and in follow-up (FU). Materials and Methods: Singe-center retrospective review of SBAS treated from 1/2007-7/2020. Clinicopathologic data was collected, including local and systemic imaging at DX and FU. The clinical impact of imaging was evaluated. Results: Twenty patients had SBAS diagnosed 10.6±6.7 years following their index BC. All were diagnosed on exam. Mammogram, ultrasound, and breast MRI were commonly performed concurrently with DX (2.4 studies per patient) but did not impact clinical management. In-breast imaging extent of disease did not correlate with pathologic extent of disease (p=0.49). Systemic staging uncommonly identified asymptomatic metastatic disease (5%). During FU, 90% of recurrences were identified by exam or new symptoms, not routine imaging. Conclusions: SBAS extent is not reliably estimated on targeted breast imaging. Asymptomatic metastatic disease is uncommon but targeted evaluation of new symptoms is warranted given high likelihood of identifying metastasis. Additional data is needed to define optimum imaging timing and modalities for SBAS.http://www.sciencedirect.com/science/article/pii/S2666262022000250Breast cancerSarcomaImagingStagingClinical outcomes |
| spellingShingle | Kelsey E. Larson Benjamin Powers Jason Gatewood Amanda L. Amin Lyndsey J. Kilgore Jamie L. Wagner Christa R. Balanoff Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma Surgery in Practice and Science Breast cancer Sarcoma Imaging Staging Clinical outcomes |
| title | Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma |
| title_full | Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma |
| title_fullStr | Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma |
| title_full_unstemmed | Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma |
| title_short | Clinical Impact of Systemic Staging Studies in Secondary Breast Angiosarcoma |
| title_sort | clinical impact of systemic staging studies in secondary breast angiosarcoma |
| topic | Breast cancer Sarcoma Imaging Staging Clinical outcomes |
| url | http://www.sciencedirect.com/science/article/pii/S2666262022000250 |
| work_keys_str_mv | AT kelseyelarson clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma AT benjaminpowers clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma AT jasongatewood clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma AT amandalamin clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma AT lyndseyjkilgore clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma AT jamielwagner clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma AT christarbalanoff clinicalimpactofsystemicstagingstudiesinsecondarybreastangiosarcoma |